US study shows that longer levofloxacin treatment may increase the relapse-free interval in patients with chronic bacterial prostatitis
A study carried out by staff at Ortho-McNeil Janssen Scientific Affairs has compared the safety and efficacy of levofloxacin, 750 mg daily for 2 or 3 weeks, with 500 mg daily for 4 weeks as a treatment for chronic bacterial prostatitis (CBP). A total of 241 subjects were enrolled and the study had a randomized, multicenter, double-blind, non-inferiority design. The clinical success rates of the treatments were all over 60% and, while there were no important differences between the different treatments, it appeared that a longer period of treatment may increase the relapse-free interval in patients with CBP.
Curr Med Res Opin. 2010 Apr 15.[Epub ahead of print]
Source : http://www.ncbi.nlm.nih.gov/pubmed/20394471?dopt=Abstract